eXciteOSA, the first FDA-authorized daytime therapy for sleep-disordered breathing, has treated over 10,000 patients since its commercial launch in 2021 by Signifier Medical.
“This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients,” says Akhil Tripathi, Signifier Medical co-founder and CEO, in a press release. “It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.”
Nasdaq recognized this milestone by congratulating Signifier Medical on the Nasdaq Tower in Times Square, New York.
Past studies have shown that eXciteOSA is associated with reductions in both objectively measured and bed-partner-reported snoring, along with significant improvements in disease severity, measured by the Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index. Clinical trial participants experienced a significant reduction in their apnea-hypopnea index overall.
Based on a recent study, eXciteOSA therapy demonstrates real-world adherence of more than 80%.
“eXciteOSA is a new and novel daytime treatment for sleep apnea. Burden of use is as low as 20 minutes. Evidence is mounting about the positive effects of eXciteOSA in improving disease severity and daytime sleepiness. Patients now have an alternative approach that is easy to use and well accepted,” says Naresh M. Punjabi, PhD, chief of the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Miami, in a press release.
eXciteOSA uses neuromuscular electrical stimulation to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep.
Randomized trials are in progress to understand the potential placebo effect, the impact of therapy relative to usual care without treatment, and the impact of therapy amongst those with moderate OSA.
Photo caption: Nasdaq recognizes Signifier Medical’s milestone by congratulating the company on the Nasdaq Tower.
Photo credit: Business Wire
